Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws

• Published in: Oral diseases 2014-07, Vol.20 (5), p.446-452
• Main Authors: Bagan, J, Sáez, GT, Tormos, MC, Hens, E, Terol, MJ, Bagan, L, Diaz-Fernández, JM, Lluch, A, Camps, C
• Format: Article
• Language: English
• Subjects: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw - blood; Bisphosphonate-Associated Osteonecrosis of the Jaw - metabolism; bisphosphonates; Body fluids; Bone diseases; Cytokines; Dentistry; Diphosphonates - administration & dosage; Female; Humans; interleukin-6; Interleukin-6 - analysis; Interleukin-6 - blood; Male; Mouth; osteonecrosis of the jaws; Plasma; Saliva - chemistry
• ISSN: 1354-523X; 1601-0825
• DOI: 10.1111/odi.12150

Aim To determine the plasma and saliva levels of IL‐6 in patients with bisphosphonate‐related osteonecrosis of the jaws (BRONJ) and to investigate whether there is a correlation between more advanced stages of BRONJ and levels of IL‐6. Material and Methods We studied three groups: group 1 consisted of 30 patients with BRONJ due to intravenous bisphosphonates (ivBP), group 2 consisted of 25 patients treated with ivBP but without BRONJ, and group 3 consisted of 15 healthy controls. In each case, we assayed plasma and saliva IL‐6 samples using an ELISA test. Results Significantly, higher IL‐6 values were found in both saliva and plasma in group 1 vs groups 2 and 3 (P  0.05), type of tumor, BRONJ location, etiology of BRONJ, or disease stage (P > 0.05). We found higher plasma and saliva IL‐6 values in the more advances stages of BRONJ, although the differences were not statistically significant. Conclusions Plasma and saliva IL‐6 values were higher in our patients with BRONJ than in controls and therefore might be a useful tool for monitoring the severity of BRONJ.